Advances in the Understanding of Amyloid-Related Imaging Abnormalities in Alzheimer’s Disease (ARIA)

Date & Time: April 24, 2024 at 12pm ET

The program is designed to enhance clinicians’ knowledge of amyloid-related imaging abnormalities (ARIA) associated with amyloid-targeting therapies for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease.

Learning Objectives
After completing this activity, the participant should be better able to:

• Explain the pathophysiology of ARIA
• Describe different types of ARIA and their clinical and imaging characteristics
• Review strategies for mitigating the risk of ARIA in patients receiving amyloid targeting therapies
• Utilize evidence-based strategies to monitor for ARIA in patients receiving amyloid targeting therapies
• Discuss best practices for communicating across the interdisciplinary care team about management of ARIA
• Define best practices and strategies for educating and communicating with patients and caregivers regarding ARIA 

Target Audience
This activity has been designed to meet the educational needs of neurologists, Alzheimer’s disease (AD) specialists, PAs, and nurse practitioners who care for patients with Alzheimer’s disease (AD).

Physician Continuing Education
PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

PA Continuing Medical Education
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

In support of improving patient care, PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is jointly provided by PACE and Catamount Medical Education and is supported by an independent educational grant from Lilly.


R. Scott Turner, PhD, MD, FANA, FAANProfessor, Department of NeurologyDirector, Memory Disorders ProgramGeorgetown University
Washington, DC